Dynavax Technologies

  www.dynavax.com
  www.dynavax.com
Work in HR? Unlock Free Profile

Dynavax Technologies Reviews

4 Reviews
3.3
4 Reviews

Recommend to a friend
Approve of CEO
(no image)
Dino Dina
3 Ratings
  1.  

    A great place to work for....

    Current Employee - Anonymous Employee
    Current Employee - Anonymous Employee

    I have been working at Dynavax Technologies

    Pros

    nice people, good benefits, room for growth/opportunities

    Cons

    Not too many cons I can think of.

Dynavax Technologies Interviews

Interview Experience

Interview Experience

100%
0%
0%

Getting an Interview

Getting an Interview

100%

Interview Difficulty

3.0
Average

Interview Difficulty

Hard

Average

Easy
  1.  

    Talent Acquisition Interview

    Anonymous Interview Candidate  in  Berkeley, CA
    Anonymous Interview Candidate in Berkeley, CA
    Application Details

    I applied online. The process took 4 weeks - interviewed at Dynavax Technologies in December 2011.

    Interview Details

    I submitted my resume on-line; was contacted by the HR Representative; went in for face to face interviews; met with various department heads;

    Interview Questions
    • Please try to be as detailed as possible regarding the technical question, business case, etc.   Answer Question
    Negotiation Details
    HR listened to the range I expected, and came in with a solid offer.
    Accepted Offer
    Positive Experience
    Average Interview

Dynavax Technologies Awards & Accolades

Let us know if we're missing any workplace or industry recognition – Add an award

Additional Info

Edit Profile
Website www.dynavax.com
Headquarters Berkeley, CA
Size 150 to 499 Employees
Founded 1996
Type Company - Public (DVAX)
Industry Biotech & Pharmaceuticals
Revenue $10 to $25 million (USD) per year

Dynavax Technologies is trying to reprogram the way the body reacts to disease. The firm focuses on immunostimulatory sequences (ISS), short strands of DNA found to strengthen the immune system. The company's lead candidate in clinical trials is HEPLISAV, a hepatitis B vaccine. Other candidates in the company's pipeline include a universal flu vaccine that would cover a wider span of flu viruses than traditional flu vaccines, as well as potential treatments for asthma, hepatitis C, and autoimmune and inflammatory diseases. To share the expense and risk of development... More

Worked for Dynavax Technologies? Contribute to the Community!